Skip to main content

Table 1 Characteristics of Study Patients

From: Detection of adverse drug events in e-prescribing and administrative health data: a validation study

  All Study Patients
(N = 688)
Patients Prescribed an Antidepressant
(N = 302)
Patients Prescribed an Antihypertensive
(N = 386)
Age, mean (SD) 64.2 (13.9) 59.5 (16.2) 67.8 (10.6)
Sex (male) 243 (35.3%) 94 (31.1%) 149 (38.6%)
Most Commonly Prescribed Drug Classes
Antidepressants
  SSRIs 117 (17.0%) 117 (38.7%) NA
  SNRIs 104 (15.1%) 104 (34.4%) NA
  SRIs 50 (7.3%) 50 (16.6%) NA
Antihypertensives
  Calcium Channel Blockers 116 (16.9%) NA 116 (30.1%)
  Angiotensin II Receptor Blockers 113 (16.4%) NA 113 (29.3%)
  Thiazide Diuretics 50 (7.3%) NA 50 (13.0%)
Most Commonly Prescribed Medications
Antidepressants
  Citalopram 90 (13.1%) 90 (29.8%) NA
  Trazodonea 50 (7.3%) 50 (16.6%) NA
  Venlafaxine 44 (6.4%) 44 (14.6%) NA
Antihypertensives
  Amlodipine 69 (10.0%) NA 69 (17.9%)
  Hydrochlorothiazide 45 (6.5%) NA 45 (11.7%)
  Telmisartan 32 (4.7%) NA 32 (8.3%)
Most Common Therapeutic Indications
Antidepressants
  Depression 121 (17.6%) 121 (40.1%) NA
  Generalized Anxiety Discorder 62 (9.0%) 62 (20.5%) NA
  Insomnia 52 (7.6%) 52 (17.2%) NA
Antihypertensives
  Hypertension 306 (44.5%) NA 306 (79.3%)
  Oedema 18 (2.6%) NA 18 (4.7%)
Number of Concurrent Medicationsb 3.7 (2.9) 3.8 (2.9) 3.7 (2.9)
Charlson Comorbidity Index Score
  0 334 (48.5%) 165 (54.6%) 169 (43.8%)
  1 166 (24.1%) 73 (24.2%) 93 (24.1%)
  2+ 188 (27.3%) 64 (21.2%) 124 (32.1%)
Most Common Comorbidities
  Chronic Pulmonary Disease 149 (21.7%) 68 (22.5%) 81 (21.0%)
  Diabetes (without complications) 105 (15.3%) 36 (11.9%) 69 (17.9%)
  Renal Disease 66 (9.6%) 21 (7.0%) 45 (11.7%)
  Congestive Heart Failure 58 (8.4%) 18 (6.0%) 40 (10.4%)
  Cerebrovascular Disease 48 (7.0%) 20 (6.6%) 28 (7.3%)
  1. Unless otherwise specified, all estimates are presented as N (%)
  2. Abbreviations: SSRIs Selective Serotonin Reuptake Inhibitors, SNRIs Serotonin-Norepinephrine Reuptake Inhibitors, SRIs Serotonin Reuptake Inhibitors, NA Not applicable
  3. a96% of prescriptions for trazodone were for an indication of insomnia
  4. bDefined as the number of medications besides the study drug that were dispensed in the 1 month following the visit in which the study drug was prescribed